This study was to investigate the role of STIM1 on metastatic potential of human CRC. Methods: We examined the expression of STIM1 in four CRC cell lines with different metastatic potentials using real-time PCR and Western Blot, SW620

and LOVO (high metastatic potential), SW480 and HT29 (low metastatic potential). Expression of STIM1 in CRC tissues was explored using immunohistochemisty. The relationships between STIM1 expression and clinicopathologic factors were assessed using theχ2 test. Effects of stable expression of STIM1 and its siRNA inhibitors were studied in the human CRC cell lines SW480 and SW620; transwell experiments were performed to evaluate cellular migration and invasion. Results: Expression of STIM1 was increased in highly invasive CRC cell lines and lymph node-positive CRC specimens. Enhancing the expression of STIM1 promoted CRC cell migration and invasion, while silencing Alectinib purchase its expression BIBW2992 supplier resulted in reduced migration and invasion. STIM1 overexpression was significantly associated

with advanced clinicalTNM stage and lymph node metastasis. Conclusion: These results suggest that STIM1 is a novel metastasis marker in CRC and might be a potential target for diagnosis and therapy. Key Word(s): 1. STIM1; 2. SOCE; 3. Colorector cancer; 4. Metastasis; Presenting Author: BANGMAO WANG Additional Authors: HAILONG CAO Corresponding Author: BANGMAO WANG Affiliations: General Hospital, Tianjin Medical University Objective: Berberine, an isoquinoline plant alkaloid, has shown antineoplastic effects on a variety of cancer cells in vitro. The aim of this study was to investigate chemopreventive effects of berberine on intestinal tumor development in APCmin/+ mice. Methods: Four-week old APCmin/+ mice were treated with 0.05% or 0.1% berberine in drinking water for twelve weeks. Parameters of intestinal tumor development, cell proliferation and apoptosis, and tumor promoting signaling pathways were determined. Results: The total number of the intestine tumor was decreased by

39.6% in 0.05% berberine treatment group 18.50 ± 1.51) and by 62.5% in 0.1% treatment group (11.50 ± 2.05) compared with untreated group (30.63 ± 1.69). All sizes of tumor (>2 mm, 1–2 mm, and <1 mm) were significantly reduced in both berberine treatment groups. selleck compound In 0.1% berberine-treated group, tumors in proximal, middle, distal segments of small intestine were significantly reduced by 53.7%, 55.3%, and 76.5%, and the percentage of PCNA and Ki-67 positive cells were decreased by 32% and 55%, respectively, expression of cyclin Dl was also decreased, and apoptotic cell number was increased by 2.14 fold in the tumors. Gene microarray indicated different gene expression profiles, and Wnt and EGFR pathways may be involved. Furthermore, berberine treatment suppressed β-catenin and epidermal growth factor receptor activation, and down-regulated the expression of cyclooxygenase-2 and prostaglandin E2 production.